The present specification relates to a novel hetero-cyclic compound, and an organic light emitting device using the same.

The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.

The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

A separator for an electrochemical cell that cycles lithium ions includes a microporous layer and one or more fire suppression layers disposed on at least one of a first side or an opposite second side of the microporous layer. The one or more fire suppression layers include a ceramic material having interconnected open pores and a cyclophosphazene disposed within the interconnected open pores of the ceramic material.

A separator for an electrochemical cell that cycles lithium ions includes a microporous layer and one or more fire suppression layers disposed on at least one of a first side or an opposite second side of the microporous layer. The one or more fire suppression layers include a ceramic material having interconnected open pores and a cyclophosphazene disposed within the interconnected open pores of the ceramic material.

The present invention relates to a compound of formula (I), which is a phosphate ester of apomorphine, or a pharmaceutically acceptable salt thereof. The apomorphine phosphate ester according to the invention exhibits remarkably advantageous properties as a therapeutic, including a favorable tolerability, an improved side effect profile, particularly a reduced occurrence of skin nodule formation and panniculitis when administered subcutaneously, as well as pharmacokinetic and metabolic properties rendering it particularly well-suited as an apomorphine prodrug. The invention further relates to the compound of formula (I) for use as a medicament, particularly for use in the treatment of Parkinson's disease.

A condensed cyclic compound which improves emission life and efficiency and an organic electroluminescence device is provided. The condensed cyclic compound according to the inventive concept is represented by the following ##STR00001## where each of X, Y and Z is independently a substituted or unsubstituted pentagonal hydrocarbon ring, a substituted or unsubstituted hexagonal hydrocarbon ring, a substituted or unsubstituted pentagonal heterocycle, or a substituted or unsubstituted hexagonal heterocycle, the pentagonal heterocycle and the hexagonal heterocycle each independently includes one heteroatom, each of a and b is independently 0 or 1, and Ar.sub.1 is a substituted or unsubstituted aryl group having 6 to 30 carbon atoms for forming a ring.